Faculty
Julia Meade, MD
Pediatric Cancer Predisposition Program Director
Associate Professor of Pediatrics and Human Genetics
Division of Hematology/Oncology and Genetic and Genomic Medicine
University of Pittsburgh School of Medicine and School of Public Health
UPMC Children’s Hospital of Pittsburgh

Julia Meade, MD, is a pediatric genetic oncologist certified in pediatric hematology/oncology by the American Board of Pediatrics. She is an associate professor of pediatrics at the University of Pittsburgh School of Medicine in both the divisions of pediatric hematology/oncology and genetic and genomic medicine. Dr. Meade holds a secondary appointment as associate professor of human genetics in the School of Public Health. She received her medical degree from Texas A&M University School of Medicine and completed her pediatric residency at the University of Colorado, followed by her hematology/oncology fellowship at UT Southwestern Medical Center and her pediatric neuro-oncology fellowship at Northwestern University. Dr. Meade also holds a certificate in cancer risk assessment from the City of Hope.  

Dr. Meade is the director of the pediatric cancer predisposition program at the University of Pittsburgh Medical Center (UPMC) Children’s Hospital of Pittsburgh, which provides diagnosis, screening and coordination of care for children with a genetically increased risk for cancer. Additionally, Dr. Meade is dedicated to the care of children with neurofibromatosis, plexiform neurofibromas and rare tumors. Dr. Meade is the principal investigator for clinical trials investigating MEK-inhibitors for children with plexiform neurofibromas. She is active in research and education surrounding cancer- predisposition syndromes, including the mentorship of multiple genetic counseling students, graduate students and medical trainees. Dr. Meade is a member of the American Society of Pediatric Hematology/Oncology, the Children’s Oncology Group, and the Adult Tumor Genes in Children and Adolescents Consortium. Dr. Meade writes poetry and narrative medicine pieces about her experiences.

Planners
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Sarah Chart, RN
Vice President
Optum Health Education

Sara Fleszar, PharmD, BCOP
Senior Clinical Pharmacist
Optum Health Solutions

Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education

Lisa Latts, MD, MSPH, MBA, FACP
Chief Medical Officer
Optum Behavioral Health Solutions & Optum Health Solutions
Optum Health Clinical Excellence
Optum

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Financial Relationship Key
 A-Advisory Board
 CT-Clinical Trial
 C-Consultant
 E-Employee
 G- Grant/Research Support or Funding
 I-Stocks and Other Ownership Interests 
 S-Speakers’ Bureau
 O-Other Financial or Material Support

Julia Meade, MD: Alexion Pharmaceuticals (C)

All relevant financial relationships have been mitigated. 

The remaining faculty and planners have no financial relationships to disclose.